Today's Date: February 1, 2023
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Avaya Holdings Corp (AVYA) Investo   •   Media Advisory: Military Veteran Receives Grant for Down Payment on First Home   •   Meijer Brings Midwest Artists' Works to Life in New Black History Month Collection Benefiting Urban Leagues   •   dozanü innovations releases "The State of Accessible Marketing in 2023" report   •   THE RCMP, CAFC AND OPP RAISE AWARENESS AFTER AN INCREASE IN EMERGENCY - GRANDPARENT SCAMS   •   Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year   •   The Cowgirl Channel Set To Launch On DISH Network and SLING TV   •   Shareholder Alert: Robbins LLP Informs Investors of Class Action Against National Vision Holdings, Inc.   •   Climate action project in the District of Kitimat gets investment from Canada and British Columbia   •   Asian Pacific Islander American Scholars Welcomes Two New Members to the Board of Directors   •   Black History Month comes to life across SiriusXM Canada   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) I   •   Louis Bull Tribe and Canada sign historic agreement to further support the well-being of First Nations children and community   •   Indianapolis-Based Marian University Selects YuJa Enterprise Video Platform to Serve as Video Content Creation and Management Sy   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of National Vision Holdings, Inc. (EY   •   IAPMO Publishes Children's Coloring Book "My Mom Is a Plumbing Superhero"   •   MGM RESORTS INTERNATIONAL HONORED AS A NATIONAL LEADER IN SUPPORTING WOMEN-OWNED BUSINESSES   •   Aris Water Solutions, Inc. Provides Fourth Quarter 2022 Business Update and Announces Date and Time for Fourth Quarter and Full   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics, Inc. (FATE) Inv   •   Bumble Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
Bookmark and Share

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England , December 05 /Businesswire/ - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 2,000 shares of KalVista common stock on December 1, 2022 as inducement material to such employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $5.34 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.


STORY TAGS: Massachusetts, Europe, United States, United Kingdom, North America, Stock Sale/Buyback, Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News